Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review

被引：31

作者：

Verhovsek M. ^{[1
]}

Motlagh B. ^{[1
]}

Crowther M.A. ^{[1
]}

Kennedy C. ^{[1
]}

Dolovich L. ^{[1
]}

Campbell G. ^{[2
]}

Wang L. ^{[3
]}

Papaioannou A. ^{[1
]}

机构：

[1] McMaster University, Hamilton, ON

[2] Medical Pharmacies Group Inc., Pickering, ON

[3] St. Joseph's Healthcare, Hamilton, ON

来源：

BMC Geriatrics | / 8卷 / 1期

关键词：

Warfarin; International Normalize Ratio; Warfarin Therapy; Target International Normalize Ratio; International Normalize Ratio Range;

D O I：

10.1186/1471-2318-8-13

中图分类号：

学科分类号：

摘要：

Background. Maintenance of therapeutic International Normalized Ratio (INR) in the community is generally poor. The supervised environment in long-term care facilities may represent a more ideal setting for warfarin therapy since laboratory monitoring, compliance, dose adjustment, and interacting medications can all be monitored and controlled. The objectives of this study were to determine how effectively warfarin was administered to a cohort of residents in long-term care facilities, to identify the proportion of residents prescribed warfarin-interacting drugs and to ascertain factors associated with poor INR control. Methods. A chart review of 105 residents receiving warfarin therapy in five long-term care facilities in Hamilton, Ontario was performed. Data were collected on INR levels, warfarin prescribing and monitoring practices, and use of interacting medications. Results. Over a 12 month period (28,555 resident-days, 78.2 resident years) 3065 INR values were available. Residents were within, below and above the therapeutic range 54%, 35% and 11% of the time, respectively. Seventy-nine percent of residents were prescribed at least one warfarin-interacting medication during the period in review. Residents receiving interacting medications spent less time in the therapeutic range (53.0% vs. 58.2%, OR = 0.93, 95% confidence interval 0.88 to 0.97, P = 0.002). Adequacy of anticoagulation varied significantly between physicians (time in therapeutic range 45.9 to 63.9%). Conclusion. In this group of long-term care residents, warfarin control was suboptimal. Both prescriber and co-prescription of interacting medications were associated with poorer INR control. Future studies should seek strategies to improve prescriber skill and decrease use of interacting medications. © 2008 Verhovsek et al; licensee BioMed Central Ltd.

引用

共 21 条

[1] Sudlow M., Thomson R., Thwaites B., Rodgers H., Kenny R.A., Prevalence of atrial fibrillation and eligibility for anticoagulants in the community, Lancet, 352, pp. 1167-1171, (1998)
[2] Stein P.D., Hull R.D., Kayali F., Ghali W.A., Alshab A.K., Olson R.E., Venous thromboembolism according to age: The impact of an aging population, Arch Intern Med, 164, pp. 2260-2265, (2004)
[3] Heeringa J., Van Der Kuip D.A., Hofman A., Kors J.A., Van Herpen G., Stricker B.H., Stijnen T., Lip G.Y., Witteman J.C., Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study, Eur Heart J, 27, pp. 949-953, (2006)
[4] Aronow W.S., Ahn C., Gutstein H., Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility, J Gerontol a Biol Sci Med Sci, 57, (2002)
[5] Heit J.A., Melton III L.J., Lohse C.M., Petterson T.M., Silverstein M.D., Mohr D.N., O'Fallon W.M., Incidence of venous thromboembolism in hospitalized patients vs community residents, Mayo Clin Proc, 76, pp. 1102-1110, (2001)
[6] Reynolds M.W., Fahrbach K., Hauch O., Wygant G., Estok R., Cella C., Nalysnyk L., Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis, Chest, 126, pp. 1938-1945, (2004)
[7] Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., Laskin C., Fortin P., Anderson D., Kearon C., Clarke A., Geerts W., Forgie M., Green D., Costantini L., Yacura W., Wilson S., Gent M., Kovacs M.J., A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome, N Engl J Med, 349, pp. 1133-1138, (2003)
[8] Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., MacKinnon B., Weitz J.I., Crowther M.A., Dolan S., Turpie A.G., Geerts W., Solymoss S., Van Nguyen P., Demers C., Kahn S.R., Kassis J., Rodger M., Hambleton J., Gent M., Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism, N Engl J Med, 349, pp. 631-639, (2003)
[9] Gottlieb L.K., Salem-Schatz S., Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?, Arch Intern Med, 154, pp. 1945-1953, (1994)
[10] Matchar D.B., Samsa G.P., Cohen S.J., Oddone E.Z., Jurgelski A.E., Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial, Am J Med, 113, pp. 42-51, (2002)

← 1 2 3 →